After word of potential Mercy sale, Baystate CEO reassures staff but points to nondisclosure, confidentiality
But Banko told staffers that management is unable to provide details.
'Potential partnership discussions or conversations of any type are always bound by nondisclosure and confidentiality agreements,' Banko, on the job for about a year, wrote to Baystate's 13,000 employees in an email Wednesday.
That day, The Republican reported that Baystate and Mercy have been talking for some time.
But details of how a merged system would work and the effects on employees and services — or if it will even happen — are not apparent.
Spokespeople at Baystate and Trinity Health of New England declined to comment on the possibility of a merger or acquisition.
The nurses' union at Mercy asked management this spring about a possible sale as part of their negotiations. Mercy's answer left open the possibility, according to a response provided by the Massachusetts Nurses Association.
The possibility of consolidation has Springfield-area elected officials worried about health care access.
Mercy, with 182 beds, serves people in Springfield's poorest communities.
Both Mercy and Baystate have high percentages of patients on Medicare and Medicaid, government insurance that pays less for care than the institutions would otherwise charge.
Mercy gets nearly 80% of its patient revenue from public payers like Medicare and Medicaid, according to Center for Health Information and Analysis data from 2023.
Baystate Medical Center is in virtually the same boat at 72.6%.
The nurses' union spokesperson said the unfolding scenario is a reminder of Trinity's quiet sale of the former Providence Hospital in Holyoke in 2021 to a for-profit operator for $4 million.
Any deal would need approvals from the Massachusetts Attorney General's Office and health officials, as well as the federal government.
Stories by Jim Kinney
Pridelands on Main St., outdoor beer garden funded through ARPA, drawing crowds
Electric rates will rise Friday
Baystate Health in talks about acquiring Mercy Medical Center, sources say
Read the original article on MassLive.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bernstein Reduces PT on UnitedHealth Group (UNH) Stock
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, Bernstein reduced the price target on the company's stock to $337 from $377, while keeping an 'Outperform' rating, as reported by The Fly. The firm reduced its estimates after the Q2 2025 report in order to reflect UnitedHealth Group Incorporated (NYSE:UNH)'s lower earnings power base in 2025. However, the firm is optimistic about the company's earnings growth, thanks to the turnaround for both the company and the sector. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) has updated its 2025 outlook. It expects revenues in the range of $445.5 billion – $448.0 billion, net earnings of at least $14.65 per share, and adjusted earnings of at least $16.00 per share. This new outlook showcases the H1 2025 performance and expectations for the balance of the year, such as higher realized and anticipated care trends. UnitedHealth Group Incorporated (NYSE:UNH) anticipates returning to earnings growth in 2026. The company's Q2 2025 revenues saw an increase of $12.8 billion YoY to $111.6 billion because of the growth within UnitedHealthcare and Optum. RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its Q2 2025 investor letter. Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH): UNH was the portfolio's weakest performer in Q2. The company's Q1 results, reported in April, showed 5% revenue growth but declining earnings as medical cost ratios rose to 84.8%. Higher-than-expected utilization in outpatient procedures, particularly among Medicare Advantage and Medicaid patients, pressured margins. The company subsequently lowered full-year guidance during its June investor update. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral
Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On July 25, Baird analyst Michael Ha reduced the price target on the company's stock to $297 from $492, while keeping a 'Neutral' rating, as reported by The Fly. This comes as part of an update on the managed care and healthcare facilities group. Notably, the firm remains increasingly cautious on Medicaid and the healthcare exchange. While the external environment has been evolving, Elevance Health, Inc. (NYSE:ELV) remains focused on managing healthcare costs, deploying targeted investments in advanced technology and value-based care delivery, and reinforcing the operational foundation, which helps the long-term value creation. A medical professional working at a computer, utilizing the company's digital solutions to improve care quality for consumers. Elevance Health, Inc. (NYSE:ELV)'s operating revenue came in at $49.4 billion in Q2 2025, reflecting a rise of $6.2 billion, or 14% compared to Q2 2024. This was because of increased premium yields in its Health Benefits segment, recently closed acquisitions, as well as growth in the Medicare Advantage membership, partially mitigated by the membership attrition in the Medicaid business. As a result of the embedded earnings power of Elevance Health, Inc. (NYSE:ELV)'s diversified Health Benefits and Carelon businesses, it expects to achieve a minimum of 12% average annual growth in adjusted diluted EPS over time. Hotchkis & Wiley, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Elevance Health, Inc. (NYSE:ELV), formerly known as Anthem, is a large health insurer, and the largest commercial health insurer. ELV is priced at a discount to the market; however, we believe it is a superior business, growing faster than gross domestic product while still returning most of its cash to shareholders. ELV reported earnings that were in line with consensus. Costs remain elevated but ELV reported signs of stabilization in Medicaid utilization trends. Management also provided guidance for stable Medicare Advantage margins in 2025. Overall, this was a positive quarter for ELV as commercial performance remains strong and it showed signs of normalization for utilization and cost trends.' While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
UBS Affirms Elevance Health's (ELV) ‘Buy' Rating on Earning Stability and Growth Prospects
Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a 'Buy' rating on the stock and a $435 price target. The positive stance follows the healthcare company's second-quarter results. 15 States with the Best Healthcare in the US The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. It also delivered $49.8 billion in revenues, beating expectations by 2.8%. Nevertheless, the company reduced its earnings per share outlook by $4.50, resulting in a $1.3 billion decrease in pretax income. Elevance also increased its 2025 medical loss ratio expectations by 90 basis points. Elevance attributes the higher medical loss expectations to worse-than-expected cost trends in the Affordable Care Act exchange and Medicaid businesses. UBS maintains a Buy rating on the stock, citing potential earnings stability and growth in the commercial and Carelon segments. Elevance Health, Inc. (NYSE:ELV) is a healthcare company dedicated to enhancing the health of individuals and communities. It offers a range of services, including health plans, clinical solutions, behavioral health, pharmacy benefits, and complex care solutions. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Medical AI Companies to Buy According to Analysts and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
